IRF7 and intrahepatic cholangiocarcinoma: Our study systematically demonstrated for the first time that FXYD3 directly binds to IRF7, ingeniously hijacking and amplifying innate immune signaling to form a robust, self‐sustaining, dual positive feedback loop that drives the malignant progression of ICC.